ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 152 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2015. The put-call ratio across all filers is 1.77 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,850,770 | -8.9% | 171,915 | +122.3% | 0.07% | -27.3% |
Q2 2023 | $3,128,013 | +31.6% | 77,348 | +30.5% | 0.10% | +35.6% |
Q1 2023 | $2,376,968 | -99.8% | 59,276 | +196.4% | 0.07% | +170.4% |
Q1 2015 | $1,242,000,000 | +13.2% | 20,000 | -20.0% | 0.03% | +42.1% |
Q4 2014 | $1,097,000,000 | – | 25,000 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |